• 2,2,2-Trichloroethanol Protein Workflows

  2026-09-14

  2,2,2-Trichloroethanol is a practical small molecule biochemical for rapid protein visualization and workflow checks in electrophoresis. This guide connects its use as a protein analysis reagent with translational neuroscience assays while clearly separating established protein applications from exploratory cross-domain applications.

• Ang II–HIF-1α–HILPDA Axis in NPC Radioresistance

  2026-09-14

  This study identifies a local angiotensin II–AGT–HIF-1α–HILPDA circuit that suppresses ferroptosis and promotes radioresistance in nasopharyngeal carcinoma. Its combination of molecular, cellular, animal, and tissue analyses supports dual targeting of angiotensin signaling and ferroptosis as a strategy for improving radiotherapy response, while also highlighting candidate biomarkers for patient stratification.

• TBXA2R–ERM Signaling in TNBC Metastasis

  2026-09-13

  The reference study identifies TBXA2R as an upstream GPCR activator of ezrin, radixin, and moesin, connecting G-protein signaling to cytoskeletal remodeling, motility, invasion, and metastatic colonization in triple-negative breast cancer. Its main practical contribution is a receptor-to-ERM framework that can guide mechanistic experiments on metastatic behavior while highlighting the need to distinguish migration phenotypes from complete metastatic progression.

• Aconitase Activity Colorimetric Assay Kit Guide

  2026-09-12

  Learn how to use the Aconitase Activity Colorimetric Assay Kit to connect TCA-cycle function, oxidative injury, and immune-cell metabolism. The workflow emphasizes practical controls, quantitative normalization, and complementary interpretation alongside the CD28-ARS2-PKM findings in activated CD8+ T cells.

• Limb Organoids Reveal How AER Signaling Organizes Fate

  2026-09-12

  The reference preprint introduces mouse embryonic stem cell-derived limb organoids, or budoids, that combine apical ectodermal ridge-like, surface ectoderm, mesodermal, and fibroblast-like properties. Its central finding is that AER-like cells do more than provide developmental signals: they coordinate local cell-fate support with tissue polarization, enabling cartilage formation at a distance.

• AP20187: Dimerization Control for Tumor-Stroma Studies

  2026-09-11

  AP20187 is a chemical inducer of dimerization that can provide temporal control over engineered signaling systems. This article develops a distinct assay strategy connecting conditional signaling to senescent cancer-associated fibroblast biology and immune suppression in breast tumors.

• Maridomycin Macrolide Activity: In Vitro and In Vivo

  2026-09-11

  The reference study established maridomycin as a broad-acting macrolide antibiotic with strong activity against many Gram-positive organisms and selected Gram-negative pathogens. By combining susceptibility testing, resistance experiments, bactericidal measurements, protein-binding analysis, and mouse infection models, it connected in vitro behavior with therapeutic activity while identifying important limitations related to cross-resistance.

• 5-(N,N-dimethyl)-Amiloride: NHE1 Assay Guide

  2026-09-10

  Use 5-(N,N-dimethyl)-Amiloride hydrochloride to separate Na+/H+ exchanger-dependent pH and sodium transport from downstream endothelial, cardiac, and hepatic phenotypes. This workflow combines isoform-aware concentration design with direct pH, sodium, permeability, and signaling readouts for more defensible mechanism studies.

• Serine/Glycine-Free Diet, Immunity, and PD-L1 Lactylation

  2026-09-10

  A 2024 Cell Metabolism study shows that serine/glycine restriction can inhibit colorectal cancer growth and increase cytotoxic T-cell accumulation, while also enabling immune escape through PD-L1 lactylation. Its preclinical findings and single-arm phase I feasibility data support further evaluation of diet–immunotherapy combinations, but randomized validation and mechanistic refinement remain necessary.

• Cathepsin B inhibitor CA-074: Practical Workflow

  2026-09-09

  CA-074 provides a selective biochemical tool for testing cathepsin B involvement in protease activity, cancer metastasis, neurotoxicity, and immune response modulation. This guide applies product-dossier specifications to assay and cell-based planning, while separating those values from workflow recommendations and avoiding claims of clinical efficacy or directly matched paper outcomes.

• PTEN mRNA Delivery to Reverse Trastuzumab Resistance

  2026-09-09

  The reference study developed tumor-microenvironment-responsive nanoparticles for systemic PTEN mRNA delivery in trastuzumab-resistant HER2-positive breast cancer. By restoring PTEN expression and suppressing constitutive PI3K/Akt signaling, the platform improved the biological response to trastuzumab and inhibited tumor progression in preclinical models.

• S63845 MCL1 Inhibitor: Apoptosis Workflow

  2026-09-08

  Build a mechanism-led apoptosis workflow around S63845 rather than relying on viability data alone. The approach combines dose-response testing, BAX/BAK pathway validation, and GET3/MCL1 perturbation to distinguish target dependence from nonspecific toxicity.

• Pseudo-modified uridine triphosphate in IVT

  2026-09-07

  Learn how Pseudo-UTP can be evaluated as a controlled UTP substitute for RNA synthesis, from reaction setup through cellular performance testing. The workflow emphasizes matched controls, pseudouridine-specific quality checks, and troubleshooting that separates nucleotide effects from template, purification, and delivery variables.

• Dasatinib Monohydrate: NET-Aware CML Research

  2026-09-07

  Dasatinib Monohydrate supports resistance-focused kinase studies and NET-aware chronic myeloid leukemia research. This article explains how to integrate BCR-ABL pharmacology with neutrophil extracellular trap measurements without overinterpreting TKI effects.

• Ferroptosis Signature and Atorvastatin in HCC

  2026-09-05

  A 2025 study combined ferroptosis-related transcriptomics, survival modeling, Connectivity Map screening, and experimental validation to develop a four-gene prognostic signature for hepatocellular carcinoma (HCC) and identify Atorvastatin as a potential ferroptosis-inducing agent. The findings support a biomarker-guided research strategy, while remaining preclinical and requiring mechanistic and clinical validation.

7940 records 1/530 page Next 12345 下5页 Last page